Skip to main content
. 2013 Apr 11;1(4):763–767. doi: 10.3892/mco.2013.102

Figure 4.

Figure 4.

In patients with stage III cancer, the 5-year recurrence-free survival (RFS) rate was 92.3% in the high-group, 69.0% in the low-group and 50.0% in the group that did not receive chemotherapy [CTx(-)]. The differences between the high- and low-groups and the high- and CTx(-) groups were considered statistically significant (P=0.006).